FDA approves GSK's three-in-one drug inhaler for COPD

  1. COPD Triple Combo Maintenance

    DE: https://copdnewstoday.com/2017/09/20/fda-approves-triple-combo...

    Read about the FDA approving GlaxoSmithKline's triple combo treatment, Trelegy Ellipta, as a maintenance therapy for COPD.
  2. FDA approves GSK's 3-in-1 Trelega …

    DE: https://www.massdevice.com/fda-approves-gsks-3-1-trelega-ellipta...

    The FDA has approved the triple inhaler developed by ... FDA approves GSK’s 3-in-1 ... that combines three active molecules in a single inhaler for COPD ...
  3. U.S. FDA approves GSK's three-in-one

    DE: http://www.businessinsider.com/r-us-fda-approves-gsks-three-in-one-drug...

    Sept 18 (Reuters) - GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of ...
  4. U.S. FDA approves GSK's three-in-one

    DE: https://finance.yahoo.com/news/u-fda-approves-gsks-three-232628044...

    (Reuters) - GlaxoSmithKline Plc (GSK.L) and Innoviva Inc (INVA.O) said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for ...
  5. FDA approves GSK's 3-in-1 Trelega

    DE: https://www.drugdeliverybusiness.com/fda-approves-gsks-3-1-trelega...

    The Trelega Ellipta dry powder inhaler uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD manage the condition. It is the first once-daily product approved in the U.S. that combines three active molecules in a single inhaler for COPD patients.
  6. U.S. FDA approves GSK's three-in-one

    DE: https://www.reuters.com/article/us-gsk-copd-fda/u-s-fda-approves...

    (Reuters) - GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).
  7. FDA approves first three-in-one inhaler

    DE: https://pulmccm.org/.../fda-approves-first-three-one-inhaler-copd

    FDA approval was based partly on the FULFIL trial, demonstrating a 35% relative reduction in moderate/severe COPD exacerbations and improvement in airflow among patients taking Trelegy Ellipta, compared to those taking the inhaled corticosteroid-long acting beta-agonist combination inhaler budesonide-formoterol.
  8. GlaxoSmithKline : U.S. FDA approves

    DE: http://www.4-traders.com/GLAXOSMITHKLINE-9590199/news/GlaxoSmithKline-U-S...

    ... U.S. FDA approves GSK's three-in-one drug ... It is designed to use three different mechanisms to help open airways of patients with severe COPD. The inhaler, ...
  9. FDA Approves Trelegy Ellipta for COPD - …

    DE: https://www.medscape.com/viewarticle/885903

    The inhaler is not intended for use in patients with asthma because its safety and efficacy have not been established in this population. It should not be initiated in patients with acutely deteriorating COPD or acute symptoms. The combination inhaler carries the same risks as those of its individual components.
  10. FDA approves expanded use for GSK's

    DE: https://pharmaphorum.com/news/fda-approves-expanded-use-for-gsks...

    Advair, known as Seretide elsewhere, is off-patent and only the FDA’s tough approach to copies of therapies combining an inhaler and a drug is keeping competitors at bay.